| 2026-05-13 |
详情>>
业绩披露：
2026年一季报每股收益-0.13美元,归母净利润-720.3万美元,同比去年增长48.05%
|
| 2026-05-13 |
财报披露：
美东时间 2026-05-13 盘后发布财报
|
| 2026-05-04 |
详情>>
内部人交易：
Rajavelu Esther股份减少25240.00股
|
| 2026-04-27 |
股东大会：
将于2026-06-23召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve until the 2029 annual meeting of stockholders;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026;
3.To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
4.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 120,000,000 shares to 240,000,000 shares;
5.To approve the Spero Therapeutics, Inc. 2026 Stock Incentive Plan.
|
| 2026-04-27 |
详情>>
股本变动：
变动后总股本5790.15万股
|
| 2026-03-26 |
详情>>
业绩披露：
2025年年报每股收益0.15美元,归母净利润857.20万美元,同比去年增长112.50%
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.41美元,归母净利润-2294.8万美元,同比去年增长51.87%
|
| 2025-08-12 |
详情>>
业绩披露：
2025年中报每股收益-0.28美元,归母净利润-1556.6万美元,同比去年增长49.02%
|
| 2025-05-29 |
复牌提示：
2025-05-28 12:07:42 停牌，复牌日期 2025-05-28 12:12:42
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.25美元,归母净利润-1386.6万美元,同比去年增长-9.45%
|
| 2025-04-28 |
股东大会：
将于2025-06-12召开股东大会
会议内容 ▼▲
- 1.The election of three Class II directors nominated by our board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until their successor has been duly elected and qualified;
2.The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;
3.The approval by an advisory vote of the compensation of our named executive officers, as disclosed in this proxy statement;
4.The approval of an amendment to our 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 3,000,000 shares;
5.The transaction of any other business that may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2025-03-27 |
详情>>
业绩披露：
2024年年报每股收益-1.27美元,归母净利润-6856.6万美元,同比去年增长-400.65%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.89美元,归母净利润-4767.8万美元,同比去年增长-67.97%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益-0.57美元,归母净利润-3053.1万美元,同比去年增长-21.25%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.24美元,归母净利润-1266.9万美元,同比去年增长4.50%
|
| 2024-04-16 |
股东大会：
将于2024-05-29召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve until the 2027 annual meeting of stockholders;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
4.To approve an amendment to the Company’s 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 3,000,000 shares.
|
| 2024-03-13 |
详情>>
业绩披露：
2023年年报每股收益0.43美元,归母净利润2280.60万美元,同比去年增长149.13%
|
| 2023-09-01 |
股东大会：
将于2023-10-05召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve until the 2026 annual meeting of stockholders;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in this proxy statement;
4.To approve by an advisory vote the frequency of holding an advisory vote on compensation of the Company’s named executive officers;
5.To approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation;
6.To approve a proposed amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to add a federal forum selection clause;
7.To approve an amendment to the Company’s 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 2,500,000 shares;
8.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2022-08-05 |
股东大会：
将于2022-09-15召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2025;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve an amendment to our 2017 Stock Incentive Plan, as amended, to increase the total number of shares of common stock authorized for issuance thereunder by 2,000,000 shares;
4.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-07-06 |
股东大会：
将于2021-08-17召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2024;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve amendments to our 2017 Stock Incentive Plan;
4.To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 60,000,000 shares to 120,000,000 shares;
5.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2020-09-30 |
股东大会：
将于2020-10-27召开股东大会
会议内容 ▼▲
- 1.To elect three directors to serve three-year terms expiring in 2023;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2019-04-26 |
股东大会：
将于2019-06-05召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2022;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-05召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2021;
2.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof.
|